Phaseline

Companies › Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MK-4208 (TERN-701)
ABL kinase inhibitor
BCR, ABL1Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNov 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06163430MK-4208 (TERN-701)Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL PositiveOncologyNov 2029

Targets

BCR (1) ABL1 (1)

Companies with the same targets

Ascentage Pharma Group Il-Yang Pharm. Takeda Incyte Biosciences International Sàrl Enliven Therapeutics Novartis Taiho Pharmaceutical Otsuka Bayer

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.